News
Wall Street’s main indices finished in the green but with lackluster gains, with the Nasdaq rising 0.27 percent, the S&P 500 ...
Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Hims & Hers Health, Inc. (NYSE: HIMS ) between April 29, 2025 and June 23, 2025, both dates inclusive (the ...
The partnership between the Danish pharmaceutical giant and the splashy telehealth firm Hims & Hers was strained from the ...
The CDMO, which has been owned by different private investors over the last decade, will use the funds to broaden its geographic reach.
On June 25, 2025, two securities class action lawsuits were filed against Hims & Hers Health, Inc. (NYSE: HIMS) and certain of ...
An Ozempic user has revealed what they believe is a 'terrifying' side effect of upping their Ozempic dose. Falling into the category of GLP-1 medications, Ozempic is FDA-approved for type two diabetes ...
15h
Vietnam Investment Review on MSNWegovy® Now Available in Singapore for Weight ManagementSINGAPORE - Media OutReach Newswire - 12 July 2025 - A significant advancement in weight management has arrived for Singaporeans. Novo Nordisk, a global healthcare company focused on defeating serious ...
New data and analyses presented at the American Diabetes Association’s annual meeting highlight the priorities for the next ...
Danish pharmaceutical company Novo Nordisk has officially launched its once-weekly injectable weight management drug, Wegovy® ...
The market for generic GLP-1 weight loss drugs in Canada is set to open up, and Hims & Hers is ready to jump in. | Novo ...
A labeling mistake has led to a nationwide recall of four different types of Ritz peanut butter cracker sandwich cartons, ...
Novo Nordisk's pipeline, especially the oral GLP-1 and Alzheimer’s trial, offers significant long-term upside. Click here to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results